Healthcare
Live Price
Offline$1.21
+2.54% today
1Y Change
-59.35%
Window
Jun 25, 2025 โ Jun 24, 2026
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cardiff Oncology, Inc. (CRDF) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $1.21 and down 59.4% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -13.2%, EPS growth of +27.4%, a dividend yield of 0.0%. What stands out right now is revenue -13.2%, EPS +27.4%, free cash flow -0.5% with operating margin -8256.3% and ROIC -105.9%. Valuation already assumes a fairly strong business story at price/sales 185.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CRDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-13.2% vs +7.6% peer median
Operating Margin
Below sector median
-8256.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -13.2% and EPS is at +27.4%, with operating margin around -8256.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 2 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.5% | +3.5% | -11.0% |
2026 Feb 24, 2026 | +38.9% | +12.4% | +11.2% | +1.8% |
2025 Nov 6, 2025 | +15.0% | -2.7% | -4.4% | -6.2% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CRDF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CRDF Max Drawdown
-73.48%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CRDF and SPY.
Company Overview
Cardiff Oncology, Inc.
NASDAQ
Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for cancers with significant unmet needs. Its lead candidate, onvansertib, is an oral, selective polo-like kinase 1 (PLK1) inhibitor primarily targeting RAS-mutated metastatic colorectal cancer (mCRC) in combination with standard-of-care chemotherapy and targeted therapies. The company advances clinical programs in this indication via its randomized Phase 2 CRDF-004 trial, evaluating onvansertib in first-line treatment settings. Additional efforts include investigator-initiated trials exploring onvansertib in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer. Cardiff Oncology Inc. operates exclusively in the United States, concentrating on oncology therapeutics that disrupt mitosis in cancer cells. Headquartered in San Diego, California, and founded in 1999, it plays a role in addressing challenging cancer subtypes through innovative targeted treatments.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.